A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring.
Level 3 - non-randomized controlled study
Prospective longitudinal observational cohort with validation in an external cohort
PubMed 30842675 · doi:10.1038/s41591-019-0381-y
What was done
Multiple omics technologies were applied to track population- and individual-level immune system dynamics in 135 healthy adults across different ages monitored longitudinally over a nine-year period. Investigators mapped cellular frequency changes to characterize an immune aging trajectory ('IMM-AGE') and evaluated its association with all-cause mortality in the Framingham Heart Study.
What was found
Individual rates of immune cell frequency changes exhibited high variability driven by baseline levels, with multiple cell subsets showing an ordered convergence toward an older adult steady-state homeostasis. The resulting IMM-AGE score characterized immune status more effectively than chronological age and predicted all-cause mortality beyond standard clinical risk factors. The abstract does not provide specific numerical effect sizes, hazard ratios, or confidence intervals.
Why it matters
It provides a biologically grounded metric of immune aging that accounts for individual-level trajectory differences and adds prognostic value for mortality beyond chronological age and standard risk factors.
Limits
The discovery cohort was small (135 individuals) and restricted to healthy adults. The abstract does not report specific quantitative estimates, statistical measures of model performance, or the sample size of the Framingham validation cohort.
Cited by
- partial The biological age of a person's immune system is the single best predictor of longevity and year of death.